Orexo

Orexo's Carbon Footprint and Climate Commitments

Orexo, a pharmaceutical preparation manufacturer headquartered in Sweden (SE), is actively engaged in managing its environmental impact, with a focus on reducing carbon emissions.

Recent Emissions Data:

• 2025: Orexo reported total global emissions of approximately 1,515,000 kg CO2e. This included about 312,000 kg CO2e from Scope 2 and approximately 916,000 kg CO2e from Scope 3. Scope 1 emissions data was not available for this year.
• 2024: Total global emissions for Orexo stood at approximately 1,563,000 kg CO2e. Scope 2 emissions were around 374,000 kg CO2e, and Scope 3 emissions totalled about 877,000 kg CO2e. Scope 1 emissions data was not disclosed.
• 2023: The company's total global emissions were approximately 1,974,000 kg CO2e, comprising about 379,000 kg CO2e from Scope 2 and approximately 1,322,000 kg CO2e from Scope 3. Scope 1 emissions data was not available for this year.
• 2022: Orexo recorded total global emissions of approximately 22,680,000 kg CO2e. This figure breaks down into about 284,000 kg CO2e for Scope 1, approximately 4,053,000 kg CO2e for Scope 2, and roughly 15,734,000 kg CO2e for Scope 3.

Emission Reduction Initiatives:

Orexo has demonstrated a commitment to reducing its environmental footprint through specific initiatives. In 2023, the company achieved a reduction of 3 percent in Scope 1 and 2 emissions compared to the 2022 baseline. This reduction was primarily driven by lower emissions stemming from sales force travel.

Scope of Disclosed Emissions:

For the reporting years indicated, Orexo has disclosed emissions data for Scope 2 and Scope 3. Scope 1 emissions data was not available for 2023, 2024, and 2025.

Industry Context:

As a pharmaceutical preparation manufacturing company, Orexo operates within an industry that faces increasing scrutiny regarding its environmental impact. Efforts to reduce greenhouse gas emissions are becoming a key aspect of corporate sustainability strategies within this sector.